Immuno Aktiengesellschaft

Baxter Aktiengesellschaft

Immuno Aktiengesellschaft Fur Chemisch-medizinische Produkte

Baxalta Gmbh

Hans Peter Schwarz

Johann J Eibl

Anton Philapitsch

Peter Turecek

Yendra Linnau

Juergen Siekmann

Alfred Weber

Ludwig Pichler

Katalin Varadi

Ewald Molinari

Miha Furlan

Bernhard Laemmle

Andrea Engelmaier

Susanne Pfeiler

Hartmut Lang

Berta Moritz

Erwin Mattes

Jurgen Siekmann

Guido Tans

Jan Rosing

A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy.

Pharmaceutical preparation containing protein C and a thrombolytically active substance

Devices and methods for removing pathogens from biological fluids

There is disclosed a purified multimerase having an indirect and a direct proteolytic activity, which converts vWF having a singlet structure to vWF having a satellite structure and is active in the presence of the serine protease inhibitor DFP or the calpain protease inhibitor Z-Leu-Leu-Tyr-CHN.sub.2, as well as a method of preparing the multimerase according to the invention.

Purified multimerase

The invention relates to a stable preparation which comprises a protein, such as thrombin, that is bound in and/or on (i.e., to) lipid vesicles and that was treated for the inactivation of potentially present viruses. Further, the invention relates to methods for the production of a stable preparation for the treatment of blood coagulation disorders, wherein a protein is bound in and/or on lipid vesicles, and the method comprises a step in which the protein lipid complex is subjected to a treatment for the inactivation of potentially present viruses.

Stable preparation for the treatment of blood coagulation disorders

The present invention provides methods, reagents, and test kits for evaluating the effect of a test composition on APC response by employing factor Va.sup.R506Q Methods and compositions for treating patients suffering from reduced APC response are also provided.

Evaluation of substances for altering and for increasing APC response

Pharmaceutical preparation containing protein C and a thrombolytically

There is disclosed an anti-plasma antibody preparation for treatment of a mammal, which preparation is capable of directly or indirectly inhibiting and/or eliminating several blood factors, a method of producing such a preparation and a method of evaluating substances for treating clotting disorders by using said anti-plasma antibody preparation. There is further disclosed a method of determining the bleeding characteristics of a mammal.

Antiplasma animal model

A pharmaceutical preparation for the prevention and treatment of blood coagulation disorders is described which is characterized in that it comprises Factor V as a native protein, derivative and/or fragment thereof and Protein S in suitable pharmaceutical carrier.

Pharmaceutical preparation for the prevention and treatment of blood

The invention provides compositions having thrombolytic effects, and comprise plasmin and a plasminogen activator. Such compositions can be administered locally or systemically. The invention also provides simple and safe therapies for thrombotic states and prevention of such states.

Thrombosis agent

The invention relates to a stable preparation which comprises a protein that is bound in and/or on lipid vesicles and that was treated for the inactivation of potentially present viruses. Further, the invention relates to methods for the production of a stable preparation for the treatment of blood coagulation disorders, wherein a protein is bound in and/or on lipid vesicles, and the method comprises a step in which the protein lipid complex is subjected to a treatment for the inactivation of potentially present viruses.

An in vivo assay for determining the potential thrombogenic activity of a test compound entails pre-treating an animal with both a hepatoxin and either a bacterial agent (whole bacteria or bacterial toxins, including endotoxins) or a bacterial agent-induced cytokine, which pre-treatment enhances sensitivity to thrombogenic substances. The sensitized animal can be used in identifying a thrombogenic substance even when it is a weak potentiator of thrombogenesis, and in detecting smaller amounts of a strong potentiator.

Bioassay for thrombogenesis and rabbit model

An improved assay for determining sensitivity to activated protein C in test samples has been developed to ensure rapid and accurate evaluations. This assay is based on measuring the conversion, by activated factor VIII within a test sample, of added factor X to an activated form. The activated protein C sensitivity of the test sample is determined by the relative inhibition of factor X conversion as compared to a control. A test sample that has decreased sensitivity to activated protein C will show relatively low inhibition, and vice versa.

Assay for determining sensitivity to activated protein C

A thrombolytic, parenterally administrable drug containing activated protein C is provided for. The drug is free of serum amyloid P, thrombin activity, infectious agents and antibodies against protein C and activated protein C.

Parenterally administrable drug having thrombolytic activity and

There is disclosed the use of protein C and/or the activation peptide of protein C for preparing a pharmaceutical preparation having anti-nociceptive activity. This pharmaceutical preparation is useful in the treatment of painful conditions caused by acute or chronic inflammatory processes (such as rheumatoid arthritis, myositis, gastritis, colitis, inflammations in the urogenital tract).

Use of protein C or the activation peptide of protein C for preparing a

There is disclosed the use of protein C or activated protein C for preparing a drug useful for the maintenance and improvement of the microcirculation in patients suffering from circulatory disturbances, in particular with the proviso that the drug does not contain any immunoglobulin G.

Growing community of inventors

Vienna, Austria

Hans Peter Schwarz